

^{Pr} Dysport
aesthetic™

OVERVIEW

ACTIVE TOXIN/LASTING RESULTS

FAST ONSET/HIGH SATISFACTION

REAL RESULTS/PORTFOLIO

Fast, natural-looking RESULTS THAT LAST*†

Dysport Aesthetic (abobotulinumtoxinA) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines and/or moderate to severe lateral canthal lines (crow's feet) in adult patients <65 years of age.¹

* Results as soon as 24 hours with a median time to onset of 3 days.

† The clinical effect of Dysport Aesthetic may last up to 4 months.² Prospective, comparative, triple-blinded, single-centre, randomized, internally controlled clinical trial in 85 patients (18-65 years) with moderate-to-severe wrinkles in the glabellar or crow's feet area. Patients were given a single injection on Day 0 with Dysport Aesthetic (20 U glabellar lines, 30 U crow's feet) and onabotulinumtoxinA (8 U glabellar lines, 10 U crow's feet) injected on opposite sides of the face.²

PART OF THE GALDERMA
AESTHETICS COLLECTION

 GALDERMA

WHERE DYSPORT AESTHETIC CAN HELP

+ Glabellar Lines (Frown Lines)¹

10 units (U) at each of
5 injection sites (total: 50 U)¹

2 injections per corrugator
muscle¹ + 1 injection in
procerus muscle¹

+ Lateral Canthal Lines (Crow's Feet)¹

10 U at each of 3 injection
sites per side (total: 30 U/side;
60 U for both sides)¹

3 injection sites per crow's
feet side¹



The
Dysport Aesthetic
difference

Fast,
NATURAL-LOOKING
results that last^{*†}

Active toxin: Dysport Aesthetic delivers a high
amount of 150 kDa active toxin in each injection³

LONG-LASTING RESULTS

Clinical effect of Dysport Aesthetic may last up to **4 months²**

FAST ONSET

Natural-looking results **as early as 24 hours¹**

HIGHLY SATISFIED PATIENTS AND CLINICIANS

97% of patients want to have Dysport Aesthetic again⁴



APPROVED FOR GLABELLAR LINES AND
LATERAL CANTHAL LINES (CROW'S FEET)¹

Patients seek aesthetic
procedures to look younger
and fresher/appear more rested⁵⁻⁷

Dysport
aesthetic™

* Results as soon as 24 hours with a median time to onset of 3 days.¹

† The clinical effect of Dysport Aesthetic may last up to 4 months.² Prospective, comparative, triple-blinded, single-centre, randomized, internally controlled clinical trial in 85 patients (18-65 years) with moderate-to-severe wrinkles in the glabellar or crow's feet area. Patients were given a single injection on Day 0 with Dysport Aesthetic (20 U: glabellar lines, 30 U: crow's feet) and onabotulinumtoxinA (8 U: glabellar lines, 10 U: crow's feet) injected on opposite sides of the face.²


A HIGH AMOUNT OF active toxin IN EACH injection³

- All BoNT-As have the **same mechanism of action**
- Clinical activity of botulinum toxins is mediated by the 150 kDa **active toxin**

HOW DO BOTULINUM TOXIN TYPE As DIFFER?

The difference is in the amount of active toxin

MORE
NANOGRAMS
OF ACTIVE TOXIN
PER ON-LABEL
GLABELLAR
DOSE




Dysport
aesthetic™

LASTING RESULTS

Efficacy

MAY LAST UP TO
4 months²

INVESTIGATORS' ASSESSMENT OF TREATMENT RESPONSE
(IMPROVEMENT ≥1 GRADE) AT MAXIMUM CONTRACTION (n=59)^{2*}



Adapted from Kassir R, et al. 2013²

83%

were still responding at
4 months²


* Prospective, comparative, triple-blinded, single-centre, randomized, internally controlled clinical trial in 85 patients (18-65 years) with moderate-to-severe wrinkles in the glabellar or crow's feet area. Patients were given a single injection on Day 0 with Dysport Aesthetic (20 U: glabellar lines, 30 U: crow's feet) and onabotulinumtoxinA (8 U: glabellar lines, 10 U: crow's feet) injected on opposite sides of the face.²

FAST ONSET

Natural-looking results

AS EARLY AS 24 hours¹

MEDIAN TIME TO ONSET OF RESPONSE WAS 3 DAYS¹



Adapted from Moy R, *et al.*, 2009⁸

At least **93%** of patients saw results by day 7 post-treatment⁸

Dysport
aesthetic™

Multicentre, phase 3, open-label, repeat-dose study to assess the long-term safety of repeat administrations of Dysport Aesthetic 50 units in the treatment of glabellar lines.⁹

HIGH

satisfaction

WITH DYSPORT AESTHETIC

LASTING PATIENT AND CLINICIAN SATISFACTION



Clinician satisfaction: **91%** mean overall practitioner satisfaction* across 5 treatment cycles⁹

* Calculated as the mean percentage across the 5 treatment cycles.⁹

Patient satisfaction: Multicentre, prospective, observational study in 533 patients (18-64 years) with moderate to severe glabellar lines at maximal frown. 48% were treatment-naïve; 51% were previously treated with a competitive botulinum toxin type A product in the same area. All patients received Dysport Aesthetic at the discretion of the investigator and subject. Satisfaction was assessed at 3 weeks and 4 months.⁴

Clinician satisfaction: Retrospective multi-country study. Satisfaction rated on a 3-point scale (satisfactory, not satisfactory, unknown) with repeated Dysport Aesthetic use in routine clinical practice (5.9-6.5 months median treatment interval).¹⁰

Real results ~

BEFORE AND AFTER

Photos are real and unretouched.



Before Dysport Aesthetic



After (Day 10)*
Area treated: glabellar lines



Before Dysport Aesthetic



After (Week 4)*
Area treated: crow's feet

* Individual results may vary.

Dysport
aesthetic™

THE GALDERMA **EXCLUSIVE** aesthetics COLLECTION

Help give patients the relaxed, refined, refreshed and renewed look they desire^{1,11-20}

RELAX




Dysport
aesthetic™

REFINE



Restylane

REFRESH



Restylane
SKINBOOSTERS™

RENEW



Sculptra

Restylane
LYFT

Restylane
DEFYNE™

Restylane
LIDOCAINE

Restylane
REFYNE™

Restylane
SILK

Restylane
KYSSE™

Restylane
VOLYME™

Restylane
SKINBOOSTERS™ VITAL

Restylane
SKINBOOSTERS™ VITAL LIGHT

For more information,
please visit
DysportCanada.ca,
Restylane.ca
and Sculptra.ca

Safety profile

TEAEs WERE GENERALLY MILD TO MODERATE AND THE MAJORITY WERE CONSIDERED UNRELATED OR UNLIKELY TO BE RELATED TO TREATMENT¹

TREATMENT-EMERGENT ADVERSE EVENTS (TEAEs) (>1% INCIDENCE) IN THE GLABELLAR REGION ¹		
	DYSPORT AESTHETIC n=2,041 (%)*	PLACEBO n=480 (%)*
Patients with at least one TEAE	852 (42)	141 (29)
EYE DISORDERS		
Eyelid ptosis	33 (2)	1 (<1)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS		
Injection site pain	69 (3)	7 (1)
Injection site bruising	34 (2)	7 (1)
INFECTIONS AND INFESTATIONS		
Nasopharyngitis	123 (6)	19 (4)
Upper respiratory tract infection	58 (3)	4 (<1)
Sinusitis	55 (3)	4 (<1)
Influenza	31 (2)	3 (<1)
NERVOUS SYSTEM DISORDERS		
Headache	110 (5)	16 (3)

* Patients who received treatment with placebo and Dysport Aesthetic are counted in both treatment columns.

TEAEs (>1% INCIDENCE) FOLLOWING THE 1 ST CYCLE OF TREATMENT FROM BOTH STUDIES IN THE CROW'S FEET REGION AT 30 U ¹		
	DYSPORT AESTHETIC n=306 (%)	PLACEBO n=137 (%)
EYE DISORDERS		
Eyelid edema	5 (1.6)	-
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS		
Injection site reactions (hematoma, pruritus and swelling)	7 (2.4)	1 (0.7)
INFECTIONS AND INFESTATIONS		
Nasopharyngitis	5 (1.7)	3 (2.2)
NERVOUS SYSTEM DISORDERS		
Headache	13 (4.3)	3 (2.2)

IMPORTANT safety information¹

CONTRAINDICATIONS:

- Patients with infection at the proposed injection sites.
- Patients with a known allergy to cow's milk protein.

MOST SERIOUS WARNINGS AND PRECAUTIONS:

Distant spread of toxin effect: The effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects, which can be life-threatening. The risk of symptoms is probably greatest in children treated for spasticity and in adults who have underlying conditions that would predispose them to these symptoms. Dysport Aesthetic should only be administered by physicians with the appropriate qualifications and experience in the treatment and the use of required equipment. Dysport Aesthetic units are non-interchangeable with other products.

OTHER RELEVANT WARNINGS AND PRECAUTIONS:

- Use only as directed.
- Do not use dosage recommendations and potency units applied to other botulinum toxin products.
- Caution in patients with neuromuscular junction disorders or when excessive weakness or atrophy is present in the target muscle, prolonged

bleeding times, surgical alterations to the facial anatomy, marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin. Muscle weakness may temporarily impair the ability to drive or operate machinery.

- Risk of muscle weakness remote to the site of injection. Extreme caution in patients with a history of underlying neurologic disorders, facial palsy, dysphagia and/or aspiration.
- Immediate medical care if swallowing, speech or respiratory disorders arise.
- Risk for transmission of Creutzfeldt-Jakob disease (CJD).
- Caution in patients with eye disorders.
- Anaphylactic reaction may occur, necessary precautions should be taken.
- Caution in pregnancy.
- Not recommended during lactation.

FOR MORE INFORMATION:

Please consult the Product Monograph at www.galderma.com/sites/g/files/jcdfhc196/files/inline-files/Dysport-aesthetic-PM-E.pdf for important information relating to adverse reactions, interactions and dosing information, which have not been discussed in this advertisement.

The Product Monograph is also available by calling us at 1-800-467-2081.

References

1. ^{Pr}Dysport Aesthetic™ Product Monograph. Galderma Canada Inc. October 24, 2018.
2. Kassir R, *et al.* Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids. *Dermatol Ther* 2013;3:179-189.
3. Ehlinger-Martin A, *et al.* Women's attitudes to beauty, aging, and the place of cosmetic procedures: insights from the QUEST Observatory. *J Cosmet Dermatol* 2016;15(1):89-94.
4. Sobanko JF, *et al.* Motivations for seeking minimally invasive cosmetic procedures in an academic outpatient setting. *Aesthet Surg J* 2015;35(8):1014-1020.
5. Gubanova E, *et al.* Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with abobotulinumtoxinA (Dysport®/Azzalure®): primary results of the APPEAL noninterventional study. *Aesth Plast Surg* 2018;42(6):1672-1680.
6. Field M, *et al.* AbobotulinumtoxinA (Dysport®), onabotulinumtoxinA (Botox®), and incobotulinumtoxinA (Xeomin®) neurotoxin content and potential implications for duration of response in patients. *Toxins* 2018;10:535;doi:10.3390/toxins10120535.
7. Molina B, *et al.* Patient satisfaction after the treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a multi-centre European observational study. *JEADV* 2015;29:1382-1388.
8. Moy R, *et al.* Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. *Arch Facial Plast Surg* 2009;11(2):77-83.
9. Rzany B, *et al.* Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. *JEADV* 2010;24(Suppl. 1):1-14.
10. Rzany B, *et al.* Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. *Dermatol Surg* 2007;33:S18-25.
11. Restylane® Lyft Lidocaine Instructions for Use.
12. Restylane® Defyne Instructions for Use.
13. Restylane® Lidocaine Instructions for Use.
14. Restylane® Refyne Instructions for Use.
15. Restylane® Silk Instructions for Use.
16. Restylane® Kysse Instructions for Use.
17. Restylane® Volyme Instructions for Use.
18. Restylane® Skinboosters™ Vital Instructions for Use.
19. Restylane® Skinboosters™ Vital Light Instructions for Use.
20. Sculptra® Instructions for Use.
21. Data on File. Galderma Canada Inc.

^{Pr}Dysport
aesthetic™

THE DYSPORT AESTHETIC DIFFERENCE



FAST ONSET
Onset of effect as soon
as **24 hours**¹

LASTING **RESULTS**

Efficacy may last up to **4 months**²

A **HIGH** AMOUNT
of **active toxin** in each **injection**³

DEPTH OF **experience**

- Over **28** years of use in **73** countries²¹
- **12,800+** patients in clinical trials²¹

A **PROVEN,** **VERSATILE** **solution**

- Glabellar lines • Lateral canthal lines



NATURAL-LOOKING RESULTS⁴

98%

thought their results
looked natural

HIGH PATIENT SATISFACTION⁴

97%

wanted Dysport
Aesthetic again